To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04649060
Title Study of Melphalan Flufenamide (Melflufen) in Combination With Daratumumab in Relapsed Refractory Multiple Myeloma (LIGHTHOUSE)
Acronym LIGHTHOUSE
Recruitment Terminated
Gender both
Phase Phase III
Variant Requirements No
Sponsors Oncopeptides AB
Indications
Therapies
Age Groups: senior | adult
Covered Countries POL | NOR | GRC | ESP | DEU | CZE | BGR


No variant requirements are available.